-
Notifications
You must be signed in to change notification settings - Fork 112
/
FHIR-ebm.xml
385 lines (385 loc) · 52.4 KB
/
FHIR-ebm.xml
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
<?xml version="1.0" encoding="UTF-8"?>
<specification xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" ballotUrl="http://hl7.org/fhir/uv/ebm/2024Jan" ciUrl="http://build.fhir.org/ig/HL7/ebm" defaultVersion="1.0.0-ballot" defaultWorkgroup="cds" gitUrl="https://github.com/HL7/ebm" url="http://hl7.org/fhir/uv/ebm">
<version code="current" url="http://build.fhir.org/ig/HL7/ebm"/>
<version code="1.0.0-ballot" url="http://hl7.org/fhir/uv/ebm/2024Jan"/>
<artifactPageExtension value="-definitions"/>
<artifactPageExtension value="-examples"/>
<artifactPageExtension value="-mappings"/>
<artifact id="Evidence/55" key="Evidence-55" name="14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)"/>
<artifact id="Citation/179628" key="Citation-179628" name="14706014 Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist."/>
<artifact id="DeviceDefinition/179899" key="DeviceDefinition-179899" name="179899"/>
<artifact id="Citation/179602" key="Citation-179602" name="18160893 Wonder woman. Like my childhood heroine, Mrs. Betty also had amazing powers."/>
<artifact id="Citation/179637" key="Citation-179637" name="18508207 A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal."/>
<artifact id="Citation/179631" key="Citation-179631" name="19029421 Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer."/>
<artifact id="Citation/179627" key="Citation-179627" name="19091394 Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial."/>
<artifact id="Citation/179603" key="Citation-179603" name="19967827 Wonder woman was Argentine and her real name was Evita."/>
<artifact id="Citation/179626" key="Citation-179626" name="22056152 Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial."/>
<artifact id="Citation/179625" key="Citation-179625" name="22502942 Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial."/>
<artifact id="Citation/179615" key="Citation-179615" name="23306100 Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial."/>
<artifact id="Citation/179623" key="Citation-179623" name="23452809 Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer."/>
<artifact id="Citation/179629" key="Citation-179629" name="23604530 A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer."/>
<artifact id="Citation/179624" key="Citation-179624" name="24598155 Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer."/>
<artifact id="Citation/179617" key="Citation-179617" name="25301760 Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019)."/>
<artifact id="Citation/179622" key="Citation-179622" name="26002607 Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra."/>
<artifact id="Citation/179621" key="Citation-179621" name="26028518 Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial."/>
<artifact id="Citation/179630" key="Citation-179630" name="26092557 Feasibility study of a randomized controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced non-castration-resistant prostate cancer."/>
<artifact id="Citation/179616" key="Citation-179616" name="26244877 Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer."/>
<artifact id="Citation/33089" key="Citation-33089" name="27222544 Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations."/>
<artifact id="Citation/179613" key="Citation-179613" name="27308831 Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis."/>
<artifact id="Citation/179601" key="Citation-179601" name="29114761 Web Exclusives. Annals Story Slam - How Wonder Woman Became My Alter Ego."/>
<artifact id="Citation/179600" key="Citation-179600" name="29114762 Web Exclusives. Annals Story Slam - Wonder Woman Is a Cartoon Character."/>
<artifact id="Citation/179599" key="Citation-179599" name="29202628 "I Kinda Feel Like Wonder Woman": An Interpretative Phenomenological Analysis of Pole Fitness and Positive Body Image."/>
<artifact id="Citation/179598" key="Citation-179598" name="29357271 Using Hawkeye from the Avengers to communicate on the eye."/>
<artifact id="Citation/179597" key="Citation-179597" name="29694275 A regressive formula of perversity: Wertham and the women of comics."/>
<artifact id="Citation/179596" key="Citation-179596" name="29694302 Introduction: "Suffering Sappho!": Lesbian content and queer female characters in comics."/>
<artifact id="Citation/179595" key="Citation-179595" name="30467172 Finding my inner Wonder Woman."/>
<artifact id="Group/33395" key="Group-33395" name="33395"/>
<artifact id="Citation/179594" key="Citation-179594" name="34871555 What Can Wonder Woman Teach Radiologists?"/>
<artifact id="Citation/33399" key="Citation-33399" name="35243488 Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis."/>
<artifact id="Citation/179605" key="Citation-179605" name="36491989 Another Georgia Wonder Woman: She Does More Astounding Tricks Than Did Lula Hurst."/>
<artifact id="Citation/179604" key="Citation-179604" name="6907780 Career guide: to change what needs changing...doesn't take Wonder Woman."/>
<artifact id="Evidence/179683" key="Evidence-179683" name="ADAS-Cog(11) EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version"/>
<artifact id="StructureDefinition/adaptation" key="StructureDefinition-adaptation" name="Adaptation"/>
<artifact id="Citation/7636" key="Citation-7636" name="Anticoagulation for COVID-19 Combined RCTs in NEJM"/>
<artifact id="StructureDefinition/artifact-approvalDate" key="StructureDefinition-artifact-approvalDate" name="ArtifactApprovalDate"/>
<artifact id="StructureDefinition/artifact-assessment-compared" key="StructureDefinition-artifact-assessment-compared" name="ArtifactAssessmentCompared"/>
<artifact id="StructureDefinition/artifact-assessment-date-as-rating" key="StructureDefinition-artifact-assessment-date-as-rating" name="ArtifactAssessmentDateAsRating"/>
<artifact id="StructureDefinition/artifact-effectivePeriod" key="StructureDefinition-artifact-effectivePeriod" name="ArtifactEffectivePeriod"/>
<artifact id="StructureDefinition/artifact-lastReviewDate" key="StructureDefinition-artifact-lastReviewDate" name="ArtifactLastReviewDate"/>
<artifact id="Group/32139" key="Group-32139" name="Bariatric_Surgery_Eligibility_Group_ADA_Recommendation_8_16"/>
<artifact id="Group/179511" key="Group-179511" name="Bariatric_Surgery_Eligibility_Group_ADA_Recommendation_8_17"/>
<artifact id="Group/172423" key="Group-172423" name="Bariatric_Surgery_RYGB_VSG_LAGB_BPD"/>
<artifact id="StructureDefinition/baseline-measure-evidence" key="StructureDefinition-baseline-measure-evidence" name="BaselineMeasureEvidence"/>
<artifact id="Evidence/179451" key="Evidence-179451" name="BaselineMeasureEvidence: Age in 2018 Norwegian Cohort Medical Group"/>
<artifact id="Evidence/179452" key="Evidence-179452" name="BaselineMeasureEvidence: Age in 2018 Norwegian Cohort Surgical Group"/>
<artifact id="Evidence/179458" key="Evidence-179458" name="BaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Medical Group"/>
<artifact id="Evidence/179457" key="Evidence-179457" name="BaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Surgical Group"/>
<artifact id="StructureDefinition/book-citation" key="StructureDefinition-book-citation" name="BookCitation"/>
<artifact id="Citation/121719" key="Citation-121719" name="BookCitation: Crossing the Quality Chasm: A New Health System for the 21st Century"/>
<artifact id="StructureDefinition/book-part-citation" key="StructureDefinition-book-part-citation" name="BookPartCitation"/>
<artifact id="Citation/139859" key="Citation-139859" name="BookPartCitation: Chapter 3 of Crossing the Quality Chasm: A New Health System for the 21st Century"/>
<artifact id="Citation/139860" key="Citation-139860" name="BookPartCitation: Chapter 3 of Crossing the Quality Chasm: A New Health System for the 21st Century - without baseCitation"/>
<artifact id="Evidence/179690" key="Evidence-179690" name="CIBIC+ EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version"/>
<artifact id="Group/12714" key="Group-12714" name="COVID_19PneumoniaHospitalizedAdult"/>
<artifact id="ArtifactAssessment/179693" key="ArtifactAssessment-179693" name="Certainty of Evidence Rating of 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)"/>
<artifact id="StructureDefinition/certainty-of-evidence" key="StructureDefinition-certainty-of-evidence" name="CertaintyOfEvidence"/>
<artifact id="StructureDefinition/characteristic-description" key="StructureDefinition-characteristic-description" name="CharacteristicDescription"/>
<artifact id="StructureDefinition/characteristic-determined-by-expression" key="StructureDefinition-characteristic-determined-by-expression" name="CharacteristicDeterminedByExpression"/>
<artifact id="StructureDefinition/characteristic-determined-by-reference" key="StructureDefinition-characteristic-determined-by-reference" name="CharacteristicDeterminedByReference"/>
<artifact id="StructureDefinition/characteristic-duration-duration" key="StructureDefinition-characteristic-duration-duration" name="CharacteristicDurationDuration"/>
<artifact id="StructureDefinition/characteristic-duration-range" key="StructureDefinition-characteristic-duration-range" name="CharacteristicDurationRange"/>
<artifact id="StructureDefinition/characteristic-instances-quantity" key="StructureDefinition-characteristic-instances-quantity" name="CharacteristicInstancesQuantity"/>
<artifact id="StructureDefinition/characteristic-instances-range" key="StructureDefinition-characteristic-instances-range" name="CharacteristicInstancesRange"/>
<artifact id="StructureDefinition/characteristic-method" key="StructureDefinition-characteristic-method" name="CharacteristicMethod"/>
<artifact id="StructureDefinition/characteristic-offset" key="StructureDefinition-characteristic-offset" name="CharacteristicOffset"/>
<artifact id="StructureDefinition/characteristic-timing" key="StructureDefinition-characteristic-timing" name="CharacteristicTiming"/>
<artifact id="StructureDefinition/characteristic-value-expression" key="StructureDefinition-characteristic-value-expression" name="CharacteristicValueExpression"/>
<artifact id="StructureDefinition/characteristic-value-uri" key="StructureDefinition-characteristic-value-uri" name="CharacteristicValueUri"/>
<artifact id="Citation/58" key="Citation-58" name="Citation for FEvIR Evidence 55: 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)"/>
<artifact id="Citation/7638" key="Citation-7638" name="Citation for FEvIR Evidence 7637: Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill COVID-19"/>
<artifact id="StructureDefinition/classification" key="StructureDefinition-classification" name="Classification"/>
<artifact id="ArtifactAssessment/179448" key="ArtifactAssessment-179448" name="Classification: Study Design for Association of Bariatric Surgery with Complications and Comorbidities JAMA 2018 Norwegian Cohort"/>
<artifact id="StructureDefinition/cohort-definition" key="StructureDefinition-cohort-definition" name="CohortDefinition"/>
<artifact id="Group/179902" key="Group-179902" name="CohortDefinition_At_least_2_risk_factors_for_stroke"/>
<artifact id="Group/179514" key="Group-179514" name="CohortDefinition_BMI_27_5_32_4_in_Asian_Americans_who_do_not_achieve_durable_weight_loss_and_improvement_in_comorbidities_without_surgery"/>
<artifact id="Group/179513" key="Group-179513" name="CohortDefinition_BMI_30_34_9_in_persons_who_do_not_achieve_durable_weight_loss_and_improvement_in_comorbidities_without_surgery"/>
<artifact id="Group/179510" key="Group-179510" name="CohortDefinition_BMI_32_5_37_4_in_Asian_Americans_who_do_not_achieve_durable_weight_loss_and_improvement_in_comorbidities_without_surgery"/>
<artifact id="Group/179509" key="Group-179509" name="CohortDefinition_BMI_35_39_9_in_persons_who_do_not_achieve_durable_weight_loss_and_improvement_in_comorbidities_without_surgery"/>
<artifact id="Group/179376" key="Group-179376" name="CohortDefinition_BMI_35_and_at_least_1_obesity_related_comorbidity"/>
<artifact id="Group/179508" key="Group-179508" name="CohortDefinition_BMI_37_5_kg_m2_in_Asian_Americans"/>
<artifact id="Group/179506" key="Group-179506" name="CohortDefinition_BMI_criteria_for_ADA_surgery_recommendation"/>
<artifact id="Group/170441" key="Group-170441" name="CohortDefinition_Cancer_of_any_kind_except_basal_cell_skin_cancer_or_cancer_in_situ_unless_documented_to_be_disease_free_for_five_years"/>
<artifact id="Group/170442" key="Group-170442" name="CohortDefinition_Cardiovascular_event"/>
<artifact id="Group/179901" key="Group-179901" name="CohortDefinition_Heart_failure_based_on_Phenotypes"/>
<artifact id="Group/179512" key="Group-179512" name="CohortDefinition_Lower_BMI_criteria_for_ADA_surgery_consideration"/>
<artifact id="Group/173249" key="Group-173249" name="CohortDefinition_Nonfatal_myocardial_infarction"/>
<artifact id="Group/173250" key="Group-173250" name="CohortDefinition_Nonfatal_stroke"/>
<artifact id="Group/179898" key="Group-179898" name="CohortDefinition_Oxygen_saturation_96_on_Boots_Finger_Pulse_Oximeter"/>
<artifact id="Group/179900" key="Group-179900" name="CohortDefinition_Oxygen_saturation_96_on_Boots_Finger_Pulse_Oximeter_with_Ranges"/>
<artifact id="Group/179507" key="Group-179507" name="CohortDefinition_Proxy_criteria_for_surgical_candidates"/>
<artifact id="Group/179375" key="Group-179375" name="CohortDefinition_Severe_obesity"/>
<artifact id="StructureDefinition/combination-method" key="StructureDefinition-combination-method" name="CombinationMethod"/>
<artifact id="StructureDefinition/combination-threshold" key="StructureDefinition-combination-threshold" name="CombinationThreshold"/>
<artifact id="StructureDefinition/comment" key="StructureDefinition-comment" name="Comment"/>
<artifact id="ArtifactAssessment/179694" key="ArtifactAssessment-179694" name="Comment on Guideline: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes by Joanne Dehnbostel 2023-11-28T15:19:01.266Z"/>
<artifact id="StructureDefinition/comparative-baseline-measure-evidence" key="StructureDefinition-comparative-baseline-measure-evidence" name="ComparativeBaselineMeasureEvidence"/>
<artifact id="Evidence/179455" key="Evidence-179455" name="ComparativeBaselineMeasureEvidence: Age in 2018 Norwegian Cohort Surgical Group vs. Medical Group"/>
<artifact id="Evidence/179456" key="Evidence-179456" name="ComparativeBaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Surgical Group vs. Medical Group"/>
<artifact id="StructureDefinition/comparative-evidence" key="StructureDefinition-comparative-evidence" name="ComparativeEvidence"/>
<artifact id="Evidence/49328" key="Evidence-49328" name="ComparativeEvidence: All-cause mortality effect of bariatric surgery in 2022 meta-analysis"/>
<artifact id="Evidence/32144" key="Evidence-32144" name="ComparativeEvidence: Bariatric Surgery effect for ADA triple outcome at 5 years (Diabetes Surgery Study)"/>
<artifact id="Evidence/104157" key="Evidence-104157" name="ComparativeEvidence: Bypass surgery effects on Additional GI surgical procedure in JAMA 2018 Norwegian cohort study"/>
<artifact id="Evidence/104098" key="Evidence-104098" name="ComparativeEvidence: Bypass surgery effects on Myocardial infarction or stroke in Swedish Obese Subjects (SOS) study"/>
<artifact id="Evidence/104155" key="Evidence-104155" name="ComparativeEvidence: Bypass surgery effects on New onset depression in JAMA 2018 Norwegian cohort study"/>
<artifact id="Evidence/104121" key="Evidence-104121" name="ComparativeEvidence: Bypass surgery effects on Remission of diabetes in JAMA 2018 Norwegian cohort study"/>
<artifact id="Evidence/104156" key="Evidence-104156" name="ComparativeEvidence: Bypass surgery effects on Treatment with opioids in JAMA 2018 Norwegian cohort study"/>
<artifact id="Evidence/47740" key="Evidence-47740" name="ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Courcoulas 2014"/>
<artifact id="Evidence/47768" key="Evidence-47768" name="ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Courcoulas 2015"/>
<artifact id="Evidence/47759" key="Evidence-47759" name="ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Cummings 2016"/>
<artifact id="Evidence/47748" key="Evidence-47748" name="ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ding 2015"/>
<artifact id="Evidence/47760" key="Evidence-47760" name="ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Dixon 2008"/>
<artifact id="Evidence/47749" key="Evidence-47749" name="ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Halperin 2014"/>
<artifact id="Evidence/47751" key="Evidence-47751" name="ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ikramuddin 2013"/>
<artifact id="Evidence/47762" key="Evidence-47762" name="ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ikramuddin 2015"/>
<artifact id="Evidence/47752" key="Evidence-47752" name="ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Liang 2013"/>
<artifact id="Evidence/47665" key="Evidence-47665" name="ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Mingrone 2012 (DIBASY) trial"/>
<artifact id="Evidence/47695" key="Evidence-47695" name="ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Mingrone 2015 (DIBASY) trial"/>
<artifact id="Evidence/47738" key="Evidence-47738" name="ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Parikh 2014"/>
<artifact id="Evidence/47758" key="Evidence-47758" name="ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Schauer 2012 (STAMPEDE) trial"/>
<artifact id="Evidence/47771" key="Evidence-47771" name="ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Schauer 2014 (STAMPEDE) trial"/>
<artifact id="Evidence/47766" key="Evidence-47766" name="ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Wentworth 2014"/>
<artifact id="Evidence/33244" key="Evidence-33244" name="ComparativeEvidence: Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis"/>
<artifact id="StructureDefinition/comparative-evidence-report" key="StructureDefinition-comparative-evidence-report" name="ComparativeEvidenceReport"/>
<artifact id="Composition/178426" key="Composition-178426" name="ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)"/>
<artifact id="StructureDefinition/comparative-evidence-report-subject" key="StructureDefinition-comparative-evidence-report-subject" name="ComparativeEvidenceReportSubject"/>
<artifact id="Group/179633" key="Group-179633" name="ComparativeEvidenceReportSubject_Association_of_Bariatric_Surgery_vs_Medical_Obesity_Treatment_With_Long_term_Medical_Complications_and_Obesity_Related_Comorbidities_2018_Norwegian_Cohort"/>
<artifact id="StructureDefinition/comparative-participant-flow" key="StructureDefinition-comparative-participant-flow" name="ComparativeParticipantFlow"/>
<artifact id="Evidence/179635" key="Evidence-179635" name="ComparativeParticipantFlow: Dropout due to stopping intervention Lofexidine vs. Placebo in opioid detoxification trial"/>
<artifact id="StructureDefinition/comparator-definition" key="StructureDefinition-comparator-definition" name="ComparatorDefinition"/>
<artifact id="Group/172424" key="Group-172424" name="ComparatorDefinition_NOT_Bariatric_Surgery_RYGB_VSG_LAGB_BPD"/>
<artifact id="Group/179785" key="Group-179785" name="ComparatorDefinition_Usual_care_pharmacologic_thromboprophylaxis"/>
<artifact id="StructureDefinition/comparator-group" key="StructureDefinition-comparator-group" name="ComparatorGroup"/>
<artifact id="Group/172939" key="Group-172939" name="ComparatorGroup_JAMA_2018_Norwegian_cohort_study_Control_cohort"/>
<artifact id="Group/172460" key="Group-172460" name="ComparatorGroup_Obese_patients_18_years_old_without_bariatric_surgery"/>
<artifact id="StructureDefinition/comparator-only-evidence" key="StructureDefinition-comparator-only-evidence" name="ComparatorOnlyEvidence"/>
<artifact id="Evidence/104385" key="Evidence-104385" name="ComparatorOnlyEvidence: Additional GI surgical procedure without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study"/>
<artifact id="Evidence/104384" key="Evidence-104384" name="ComparatorOnlyEvidence: All-cause mortality without bariatric surgery in 2022 meta-analysis"/>
<artifact id="Evidence/104397" key="Evidence-104397" name="ComparatorOnlyEvidence: Myocardial infarction or stroke without bariatric surgery (Control Group) in Swedish Obese Subjects (SOS) study"/>
<artifact id="Evidence/104395" key="Evidence-104395" name="ComparatorOnlyEvidence: New onset depression without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study"/>
<artifact id="Evidence/104396" key="Evidence-104396" name="ComparatorOnlyEvidence: Remission of diabetes without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study"/>
<artifact id="Evidence/104394" key="Evidence-104394" name="ComparatorOnlyEvidence: Treatment with opioids without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study"/>
<artifact id="StructureDefinition/comparison" key="StructureDefinition-comparison" name="Comparison"/>
<artifact id="ArtifactAssessment/179700" key="ArtifactAssessment-179700" name="Comparison: Original and Adapted Recommendation: ADA Obesity Management Recommendation 8.16"/>
<artifact id="ArtifactAssessment/171898" key="ArtifactAssessment-171898" name="Composite Rating of FOI 153881 for Project FOI 112280"/>
<artifact id="StructureDefinition/composite-rating" key="StructureDefinition-composite-rating" name="CompositeRating"/>
<artifact id="Organization/118079" key="Organization-118079" name="Computable_Publishing_LLC"/>
<artifact id="Evidence/7637" key="Evidence-7637" name="Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill patients with COVID-19"/>
<artifact id="StructureDefinition/data-dictionary" key="StructureDefinition-data-dictionary" name="DataDictionary"/>
<artifact id="CodeSystem/181451" key="CodeSystem-181451" name="DataDictionary: Measuring the Rate of Scientific Knowledge Transfer"/>
<artifact id="CodeSystem/179650" key="CodeSystem-179650" name="DataDictionary: phs003190"/>
<artifact id="StructureDefinition/database-citation" key="StructureDefinition-database-citation" name="DatabaseCitation"/>
<artifact id="Citation/29812" key="Citation-29812" name="DatabaseCitation: Citation for FEvIR Platform"/>
<artifact id="StructureDefinition/database-entry-citation" key="StructureDefinition-database-entry-citation" name="DatabaseEntryCitation"/>
<artifact id="Citation/179558" key="Citation-179558" name="DatabaseEntryCitation: ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)"/>
<artifact id="StructureDefinition/dataset-citation" key="StructureDefinition-dataset-citation" name="DatasetCitation"/>
<artifact id="Citation/179559" key="Citation-179559" name="DatasetCitation: Extrachromosomal DNA Amplification Contributes to Small Cell Lung Cancer Heterogeneity and is Associated with Worse Outcomes"/>
<artifact id="StructureDefinition/date-as-rating" key="StructureDefinition-date-as-rating" name="DateAsRating"/>
<artifact id="ArtifactAssessment/181452" key="ArtifactAssessment-155969" name="DateOfFirstPublication Classification of FOI 153881 by Rachel Couban"/>
<artifact id="Citation/153881" key="Citation-153881" name="Delany-Moretlwe 2022 clinical trial"/>
<artifact id="ValueSet/179430" key="ValueSet-179430" name="EBMImplementationGuideProfile Value Set"/>
<artifact id="Group/179897" key="Group-179897" name="EGFR_45_59"/>
<artifact id="StructureDefinition/endpoint-analysis-plan" key="StructureDefinition-endpoint-analysis-plan" name="EndpointAnalysisPlan"/>
<artifact id="CodeSystem/179423" key="CodeSystem-179423" name="Evidence Based Medicine on FHIR Implementation Guide Code System"/>
<artifact id="ValueSet/evidence-variable-role-subtype" key="ValueSet-evidence-variable-role-subtype" name="Evidence Variable Role Subtype Value Set"/>
<artifact id="StructureDefinition/evidence-list" key="StructureDefinition-evidence-list" name="EvidenceList"/>
<artifact id="List/179800" key="List-179800" name="EvidenceList: Effect estimates for meta-analysis (Biegel 2020, Wang 2020, SOLIDARITY)"/>
<artifact id="List/179470" key="List-179470" name="EvidenceList: Study results included in Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis"/>
<artifact id="StructureDefinition/evidence-map" key="StructureDefinition-evidence-map" name="EvidenceMap"/>
<artifact id="Composition/104213" key="Composition-104213" name="EvidenceMap: Bariatric Surgery Summary of Findings Example for GIN 2022"/>
<artifact id="StructureDefinition/evidence-r6" key="StructureDefinition-evidence-r6" name="EvidenceR6"/>
<artifact id="StructureDefinition/evidence-report" key="StructureDefinition-evidence-report" name="EvidenceReport"/>
<artifact id="ValueSet/179431" key="ValueSet-179431" name="EvidenceReportSectionCode Value Set"/>
<artifact id="StructureDefinition/evidence-report-subject" key="StructureDefinition-evidence-report-subject" name="EvidenceReportSubject"/>
<artifact id="Group/179562" key="Group-179562" name="EvidenceReportSubject_Clinical_Outcomes_for_Effects_of_Bariatric_Surgery"/>
<artifact id="StructureDefinition/evidence-synthesis-evidence" key="StructureDefinition-evidence-synthesis-evidence" name="EvidenceSynthesisEvidence"/>
<artifact id="StructureDefinition/evidence-variable-category-value-reference" key="StructureDefinition-evidence-variable-category-value-reference" name="EvidenceVariableCategoryValueReference"/>
<artifact id="StructureDefinition/evidence-variable-definition" key="StructureDefinition-evidence-variable-definition" name="EvidenceVariableDefinition"/>
<artifact id="ValueSet/179424" key="ValueSet-179424" name="EvidenceVariableRoleSubtype Value Set"/>
<artifact id="Evidence/179691" key="Evidence-179691" name="Example EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version"/>
<artifact id="StructureDefinition/exposure-definition" key="StructureDefinition-exposure-definition" name="ExposureDefinition"/>
<artifact id="Group/179786" key="Group-179786" name="ExposureDefinition_Therapeutic_dose_anticoagulation_with_heparin"/>
<artifact id="StructureDefinition/exposure-group" key="StructureDefinition-exposure-group" name="ExposureGroup"/>
<artifact id="Group/172934" key="Group-172934" name="ExposureGroup_JAMA_2018_Norwegian_cohort_study_Surgery_cohort"/>
<artifact deprecated="true" id="StructureDefinition/exposure-variable" key="StructureDefinition-exposure-variable" name="ExposureVariable"/>
<artifact id="EvidenceVariable/179449" key="EvidenceVariable-179449" name="ExposureVariable: Age (as continuous variable)"/>
<artifact id="EvidenceVariable/179450" key="EvidenceVariable-179450" name="ExposureVariable: Body Mass Index (as continuous variable)"/>
<artifact id="EvidenceVariable/179662" key="EvidenceVariable-179662" name="ExposureVariable: pht013093.v1.p1 Age at diagnosis"/>
<artifact id="EvidenceVariable/179661" key="EvidenceVariable-179661" name="ExposureVariable: pht013093.v1.p1 RACE"/>
<artifact id="EvidenceVariable/179658" key="EvidenceVariable-179658" name="ExposureVariable: pht013093.v1.p1 SEX"/>
<artifact id="EvidenceVariable/179649" key="EvidenceVariable-179649" name="ExposureVariable: pht013093.v1.p1 SUBJECT_ID"/>
<artifact id="EvidenceVariable/179680" key="EvidenceVariable-179680" name="ExposureVariable: pht013094.v1.p1 ANALYTE_TYPE"/>
<artifact id="EvidenceVariable/179678" key="EvidenceVariable-179678" name="ExposureVariable: pht013094.v1.p1 BODY_SITE"/>
<artifact id="EvidenceVariable/179682" key="EvidenceVariable-179682" name="ExposureVariable: pht013094.v1.p1 IS_TUMOR"/>
<artifact id="EvidenceVariable/179677" key="EvidenceVariable-179677" name="ExposureVariable: pht013094.v1.p1 SAMPLE_ID"/>
<artifact id="EvidenceVariable/179679" key="EvidenceVariable-179679" name="ExposureVariable: pht013094.v1.p1 SAMPLE_USE"/>
<artifact id="EvidenceVariable/179681" key="EvidenceVariable-179681" name="ExposureVariable: pht013094.v1.p1 Source_Type"/>
<artifact id="StructureDefinition/group-assignment" key="StructureDefinition-group-assignment" name="GroupAssignment"/>
<artifact id="EvidenceVariable/172427" key="EvidenceVariable-172427" name="GroupAssignment: Bariatric Surgery vs. no bariatric surgery"/>
<artifact id="EvidenceVariable/172479" key="EvidenceVariable-172479" name="GroupAssignment: Roux-en-Y gastric bypass or Biliopancreatic Diversion vs. medical treatment"/>
<artifact id="EvidenceVariable/172481" key="EvidenceVariable-172481" name="GroupAssignment: Roux-en-Y gastric bypass surgery vs. Lifestyle-intensive medical management intervention alone"/>
<artifact id="EvidenceVariable/172478" key="EvidenceVariable-172478" name="GroupAssignment: Roux-en-Y gastric bypass vs. medical treatment"/>
<artifact id="EvidenceVariable/179784" key="EvidenceVariable-179784" name="GroupAssignment: Therapeutic-dose anticoagulation with heparin vs. Usual-care pharmacologic thromboprophylaxis"/>
<artifact id="EvidenceVariable/179689" key="EvidenceVariable-179689" name="GroupAssignment: high dose xanomeline vs. low dose xanomeline vs. placebo"/>
<artifact id="StructureDefinition/group-r6" key="StructureDefinition-group-r6" name="GroupR6"/>
<artifact id="StructureDefinition/guideline" key="StructureDefinition-guideline" name="Guideline"/>
<artifact id="Composition/179465" key="Composition-179465" name="Guideline: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes"/>
<artifact id="ActivityDefinition/213" key="ActivityDefinition-213" name="IV remdesivir 200 mg then 100 mg/day for 9 days"/>
<artifact id="EvidenceVariable/33245" key="EvidenceVariable-33245" name="InterventionDefinition: Bariatric Surgery (RYGB, VSG, LAGB, BPD)"/>
<artifact id="EvidenceVariable/33394" key="EvidenceVariable-33394" name="InterventionDefinition: NOT Bariatric Surgery (RYGB, VSG, LAGB, BPD)"/>
<artifact id="StructureDefinition/intervention-only-evidence" key="StructureDefinition-intervention-only-evidence" name="InterventionOnlyEvidence"/>
<artifact id="Evidence/104398" key="Evidence-104398" name="InterventionOnlyEvidence: Additional GI surgical procedure with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study"/>
<artifact id="Evidence/104400" key="Evidence-104400" name="InterventionOnlyEvidence: New onset depression with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study"/>
<artifact id="Evidence/104401" key="Evidence-104401" name="InterventionOnlyEvidence: Remission of diabetes with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study"/>
<artifact id="Evidence/104402" key="Evidence-104402" name="InterventionOnlyEvidence: Treatment with opioids with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study"/>
<artifact id="EvidenceVariable/159673" key="EvidenceVariable-159673" name="Investigator"/>
<artifact id="EvidenceVariable/156673" key="EvidenceVariable-156673" name="Investigator-by-treatment interaction for ADAS-Cog(11) ANCOVA"/>
<artifact id="ArtifactAssessment/179698" key="ArtifactAssessment-179698" name="Joanne Dehnbostel's Adaptation Report of Recommendation: ADA Obesity Management Recommendation 8.16"/>
<artifact id="StructureDefinition/journal-article-citation" key="StructureDefinition-journal-article-citation" name="JournalArticleCitation"/>
<artifact id="Citation/32137" key="Citation-32137" name="JournalArticleCitation: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes"/>
<artifact id="Citation/104116" key="Citation-104116" name="JournalArticleCitation: Association of Bariatric Surgery with Complications and Comorbidities JAMA 2018 Norwegian Cohort"/>
<artifact deprecated="true" id="Citation/33090" key="Citation-33090" name="JournalArticleCitation: Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations"/>
<artifact id="ArtifactAssessment/179469" key="ArtifactAssessment-179469" name="Justification for Recommendation: ADA Obesity Management Recommendation 8.16"/>
<artifact id="ArtifactAssessment/179515" key="ArtifactAssessment-179515" name="Justification for Recommendation: ADA Obesity Management Recommendation 8.17"/>
<artifact id="Composition/181448" key="Composition-181448" name="M11 Report Template Instructions"/>
<artifact id="StructureDefinition/m11-report" key="StructureDefinition-m11-report" name="M11Report"/>
<artifact id="StructureDefinition/metaanalysis-eligibility-criteria" key="StructureDefinition-metaanalysis-eligibility-criteria" name="MetaanalysisEligibilityCriteria"/>
<artifact id="Group/175766" key="Group-175766" name="MetaanalysisEligibilityCriteria_Mean_difference_in_HbA1c_effect_of_bariatric_surgery_in_type_2_diabetes_and_elevated_BMI_in_2016_meta_analysis"/>
<artifact id="StructureDefinition/metaanalysis-outcome-definition" key="StructureDefinition-metaanalysis-outcome-definition" name="MetaanalysisOutcomeDefinition"/>
<artifact id="Group/175765" key="Group-175765" name="MetaanalysisOutcomeDefinition_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_at_end_of_follow_up"/>
<artifact id="StructureDefinition/metaanalysis-study-group" key="StructureDefinition-metaanalysis-study-group" name="MetaanalysisStudyGroup"/>
<artifact id="Group/179799" key="Group-179799" name="MetaanalysisStudyGroup_Effect_Estimates_for_Mortality_at_14_days_from_COVID19_Remdesivir_vs_Placebo_RCTs"/>
<artifact id="EvidenceVariable/12719" key="EvidenceVariable-12719" name="Mortality at 14 days"/>
<artifact id="StructureDefinition/net-effect-contribution" key="StructureDefinition-net-effect-contribution" name="NetEffectContribution"/>
<artifact id="Evidence/179591" key="Evidence-179591" name="NetEffectContribution: Additional GI surgical procedure for Example for GIN 2022"/>
<artifact id="Evidence/179586" key="Evidence-179586" name="NetEffectContribution: All-cause mortality for Example for GIN 2022"/>
<artifact id="Evidence/179589" key="Evidence-179589" name="NetEffectContribution: New onset depression for Example for GIN 2022"/>
<artifact id="Evidence/179587" key="Evidence-179587" name="NetEffectContribution: Nonfatal myocardial infarction or stroke for Example for GIN 2022"/>
<artifact id="Evidence/179588" key="Evidence-179588" name="NetEffectContribution: Remission of diabetes for Example for GIN 2022"/>
<artifact id="Evidence/179590" key="Evidence-179590" name="NetEffectContribution: Treatment with opioids for Example for GIN 2022"/>
<artifact id="StructureDefinition/net-effect-contribution-list" key="StructureDefinition-net-effect-contribution-list" name="NetEffectContributionList"/>
<artifact id="List/179585" key="List-179585" name="NetEffectContributionList: Bariatric Surgery Example for GIN 2022"/>
<artifact id="StructureDefinition/net-effect-contributions" key="StructureDefinition-net-effect-contributions" name="NetEffectContributions"/>
<artifact id="Group/179584" key="Group-179584" name="NetEffectContributions_Bariatric_Surgery_Example_for_GIN_2022"/>
<artifact id="StructureDefinition/net-effect-estimate" key="StructureDefinition-net-effect-estimate" name="NetEffectEstimate"/>
<artifact id="Evidence/179583" key="Evidence-179583" name="NetEffectEstimate: Bariatric Surgery Example for GIN 2022"/>
<artifact id="StructureDefinition/non-comparative-evidence" key="StructureDefinition-non-comparative-evidence" name="NonComparativeEvidence"/>
<artifact id="EvidenceVariable/7753" key="EvidenceVariable-7753" name="Organ support-free days"/>
<artifact id="ArtifactAssessment/104064" key="ArtifactAssessment-104064" name="Outcome Importance Rating 100 of All-cause mortality"/>
<artifact id="ArtifactAssessment/104192" key="ArtifactAssessment-104192" name="Outcome Importance Rating 30 of Nonfatal myocardial infarction or stroke"/>
<artifact id="ArtifactAssessment/104194" key="ArtifactAssessment-104194" name="Outcome Importance Rating 5 of New onset depression"/>
<artifact id="ArtifactAssessment/104193" key="ArtifactAssessment-104193" name="Outcome Importance Rating 5 of Remission of diabetes"/>
<artifact id="ArtifactAssessment/104195" key="ArtifactAssessment-104195" name="Outcome Importance Rating 5 of Treatment with opioids"/>
<artifact id="ArtifactAssessment/104196" key="ArtifactAssessment-104196" name="Outcome Importance Rating 8 of Additional GI surgical procedure"/>
<artifact id="StructureDefinition/outcome-definition" key="StructureDefinition-outcome-definition" name="OutcomeDefinition"/>
<artifact id="Group/172480" key="Group-172480" name="OutcomeDefinition_American_Diabetes_Association_composite_triple_end_point_for_metabolic_control"/>
<artifact id="Group/173252" key="Group-173252" name="OutcomeDefinition_Diabetes_in_remission"/>
<artifact id="Group/172484" key="Group-172484" name="OutcomeDefinition_HbA1c_at_12_months"/>
<artifact id="Group/172477" key="Group-172477" name="OutcomeDefinition_HbA1c_at_24_months"/>
<artifact id="Group/173245" key="Group-173245" name="OutcomeDefinition_HbA1c_at_36_months"/>
<artifact id="Group/172476" key="Group-172476" name="OutcomeDefinition_HbA1c_at_60_months"/>
<artifact id="Group/175762" key="Group-175762" name="OutcomeDefinition_HbA1c_at_6_months"/>
<artifact id="Group/173251" key="Group-173251" name="OutcomeDefinition_New_onset_depression"/>
<artifact id="Group/173248" key="Group-173248" name="OutcomeDefinition_Nonfatal_myocardial_infarction_or_stroke"/>
<artifact id="StructureDefinition/outcome-importance" key="StructureDefinition-outcome-importance" name="OutcomeImportance"/>
<artifact id="StructureDefinition/outcome-list" key="StructureDefinition-outcome-list" name="OutcomeList"/>
<artifact id="List/179579" key="List-179579" name="OutcomeList: Clinical Outcomes for Effects of Bariatric Surgery"/>
<artifact deprecated="true" id="StructureDefinition/outcome-measure-evidence" key="StructureDefinition-outcome-measure-evidence" name="OutcomeMeasureEvidence"/>
<artifact deprecated="true" id="StructureDefinition/outcome-variable" key="StructureDefinition-outcome-variable" name="OutcomeVariable"/>
<artifact id="EvidenceVariable/32143" key="EvidenceVariable-32143" name="OutcomeVariable: American Diabetes Association composite triple end point for metabolic control at 5 years"/>
<artifact id="EvidenceVariable/173243" key="EvidenceVariable-173243" name="OutcomeVariable: HbA1c at 12 months"/>
<artifact id="EvidenceVariable/173246" key="EvidenceVariable-173246" name="OutcomeVariable: HbA1c at 24 months"/>
<artifact id="EvidenceVariable/173244" key="EvidenceVariable-173244" name="OutcomeVariable: HbA1c at 36 months"/>
<artifact id="EvidenceVariable/175763" key="EvidenceVariable-175763" name="OutcomeVariable: HbA1c at 6 months"/>
<artifact id="EvidenceVariable/173247" key="EvidenceVariable-173247" name="OutcomeVariable: HbA1c at 60 months"/>
<artifact id="EvidenceVariable/46025" key="EvidenceVariable-46025" name="OutcomeVariable: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups at end of follow-up"/>
<artifact id="EvidenceVariable/104118" key="EvidenceVariable-104118" name="OutcomeVariable: New onset depression"/>
<artifact id="EvidenceVariable/104097" key="EvidenceVariable-104097" name="OutcomeVariable: Nonfatal myocardial infarction or stroke"/>
<artifact id="EvidenceVariable/104117" key="EvidenceVariable-104117" name="OutcomeVariable: Remission of diabetes"/>
<artifact id="EvidenceVariable/104120" key="EvidenceVariable-104120" name="OutcomeVariable_Additional_GI_surgical_procedure"/>
<artifact id="EvidenceVariable/49217" key="EvidenceVariable-49217" name="OutcomeVariable_All_cause_mortality"/>
<artifact id="EvidenceVariable/104119" key="EvidenceVariable-104119" name="OutcomeVariable_Treatment_with_opioids"/>
<artifact id="StructureDefinition/participant-flow" key="StructureDefinition-participant-flow" name="ParticipantFlow"/>
<artifact id="Evidence/179460" key="Evidence-179460" name="ParticipantFlow: 2018 Norwegian Cohort Excluded from Analysis"/>
<artifact id="Evidence/179462" key="Evidence-179462" name="ParticipantFlow: 2018 Norwegian Cohort Included in Analysis"/>
<artifact id="Evidence/179464" key="Evidence-179464" name="ParticipantFlow: 2018 Norwegian Cohort Medical Group Included in Analysis"/>
<artifact id="Evidence/179463" key="Evidence-179463" name="ParticipantFlow: 2018 Norwegian Cohort Surgical Group Included in Analysis"/>
<artifact id="StructureDefinition/participant-flow-measure" key="StructureDefinition-participant-flow-measure" name="ParticipantFlowMeasure"/>
<artifact id="EvidenceVariable/179636" key="EvidenceVariable-179636" name="ParticipantFlowMeasure: Dropout due to stopping intervention"/>
<artifact id="EvidenceVariable/179459" key="EvidenceVariable-179459" name="ParticipantFlowMeasure: Exclusion from analysis"/>
<artifact id="EvidenceVariable/179461" key="EvidenceVariable-179461" name="ParticipantFlowMeasure: Inclusion in analysis"/>
<artifact id="Group/7750" key="Group-7750" name="Participants_in_Anticoagulation_for_COVID_19_Combined_ATTACC_ACTIV_4a_and_REMAP_CAP_RCT_hospitalized_not_critically_ill"/>
<artifact id="Group/7749" key="Group-7749" name="Patients_who_are_hospitalized_for_COVID_19_and_who_are_not_critically_ill"/>
<artifact id="EvidenceVariable/12718" key="EvidenceVariable-12718" name="Placebo"/>
<artifact id="PlanDefinition/179468" key="PlanDefinition-179468" name="PlanDefinition for Recommendation: ADA Obesity Management Recommendation 8.16"/>
<artifact id="PlanDefinition/179554" key="PlanDefinition-179554" name="PlanDefinition for Recommendation: ADA Obesity Management Recommendation 8.17"/>
<artifact id="StructureDefinition/preprint-citation" key="StructureDefinition-preprint-citation" name="PreprintCitation"/>
<artifact id="Citation/5296" key="Citation-5296" name="PreprintCitation: Nigella Sativa for COVID-19 OSF Preprint"/>
<artifact id="StructureDefinition/rating" key="StructureDefinition-rating" name="Rating"/>
<artifact id="StructureDefinition/recommendation" key="StructureDefinition-recommendation" name="Recommendation"/>
<artifact id="ValueSet/recommendation-justification-classifier" key="ValueSet-recommendation-justification-classifier" name="Recommendation Justification Classifier Codes Value Set"/>
<artifact id="CodeSystem/27834" key="CodeSystem-27834" name="Recommendation Justification Code System"/>
<artifact id="Composition/179466" key="Composition-179466" name="Recommendation: ADA Obesity Management Recommendation 8.16"/>
<artifact id="Composition/179699" key="Composition-179699" name="Recommendation: ADA Obesity Management Recommendation 8.16-adapted"/>
<artifact id="Composition/179467" key="Composition-179467" name="Recommendation: ADA Obesity Management Recommendation 8.17"/>
<artifact id="StructureDefinition/recommendation-action" key="StructureDefinition-recommendation-action" name="RecommendationAction"/>
<artifact id="StructureDefinition/recommendation-eligibility-criteria" key="StructureDefinition-recommendation-eligibility-criteria" name="RecommendationEligibilityCriteria"/>
<artifact id="StructureDefinition/recommendation-justification" key="StructureDefinition-recommendation-justification" name="RecommendationJustification"/>
<artifact id="StructureDefinition/recommendation-plan" key="StructureDefinition-recommendation-plan" name="RecommendationPlan"/>
<artifact id="EvidenceVariable/12717" key="EvidenceVariable-12717" name="Remdesivir"/>
<artifact id="Group/179783" key="Group-179783" name="Remdesivir_IV_200_mg_once_then_100_mg_once_daily_for_9_days"/>
<artifact id="ValueSet/181524" key="ValueSet-risk-of-bias-type" name="Risk Of Bias Type Value Set"/>
<artifact id="ArtifactAssessment/179692" key="ArtifactAssessment-179692" name="Risk of Bias Assessment of Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill patients with COVID-19"/>
<artifact id="StructureDefinition/risk-of-bias" key="StructureDefinition-risk-of-bias" name="RiskOfBias"/>
<artifact id="CodeSystem/181513" key="CodeSystem-181513" name="Scientific Evidence Code System (SEVCO) -- EXAMPLE VERSION for EBMonFHIR Implementation Guide"/>
<artifact id="StructureDefinition/search-results" key="StructureDefinition-search-results" name="SearchResults"/>
<artifact id="Library/179606" key="Library-179606" name="SearchResults: PubMed search for Wonder Woman"/>
<artifact id="StructureDefinition/search-strategy" key="StructureDefinition-search-strategy" name="SearchStrategy"/>
<artifact id="Group/179592" key="Group-179592" name="SearchStrategy_PubMed_and_Embase_search_for_van_Veldhuisen_2022_systematic_review"/>
<artifact id="Group/179593" key="Group-179593" name="SearchStrategy_PubMed_search_for_Wonder_Woman"/>
<artifact id="Group/178427" key="Group-178427" name="Severely_Obese_Adults_2018_Norwegian_Cohort"/>
<artifact id="StructureDefinition/single-study-evidence" key="StructureDefinition-single-study-evidence" name="SingleStudyEvidence"/>
<artifact id="StructureDefinition/soa-plandefinition" key="StructureDefinition-soa-plandefinition" name="SoaPlanDefinition"/>
<artifact id="PlanDefinition/181450" key="PlanDefinition-181450" name="SoaPlanDefinition: Follow-up assessment 3 months after study start"/>
<artifact id="StructureDefinition/software-citation" key="StructureDefinition-software-citation" name="SoftwareCitation"/>
<artifact id="Citation/179560" key="Citation-179560" name="SoftwareCitation: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"/>
<artifact id="StructureDefinition/statistic-model-applied" key="StructureDefinition-statistic-model-applied" name="StatisticModelApplied"/>
<artifact id="StructureDefinition/statistic-model-expression" key="StructureDefinition-statistic-model-expression" name="StatisticModelExpression"/>
<artifact id="StructureDefinition/statistic-model-include-if" key="StructureDefinition-statistic-model-include-if" name="StatisticModelIncludeIf"/>
<artifact id="StructureDefinition/statistic-model-intended" key="StructureDefinition-statistic-model-intended" name="StatisticModelIntended"/>
<artifact id="StructureDefinition/statistic-model-value-codeableconcept" key="StructureDefinition-statistic-model-value-codeableconcept" name="StatisticModelValueCodeableConcept"/>
<artifact id="StructureDefinition/statistic-model-value-quantity" key="StructureDefinition-statistic-model-value-quantity" name="StatisticModelValueQuantity"/>
<artifact id="StructureDefinition/statistic-model-value-range" key="StructureDefinition-statistic-model-value-range" name="StatisticModelValueRange"/>
<artifact id="Citation/33400" key="Citation-33400" name="StudyCitation: 2022 Systematic Review of bariatric surgery mortality effect 35243488"/>
<artifact id="StructureDefinition/study-eligibility-criteria" key="StructureDefinition-study-eligibility-criteria" name="StudyEligibilityCriteria"/>
<artifact id="Group/170443" key="Group-170443" name="StudyEligibilityCriteria_Eligibility_Criteria_for_Bariatric_Surgery_Randomized_Trial_Diabetes_Surgery_Study"/>
<artifact id="Group/172461" key="Group-172461" name="StudyEligibilityCriteria_Eligibility_Criteria_for_DIBASY_Trial"/>
<artifact id="Group/171819" key="Group-171819" name="StudyEligibilityCriteria_Obese_patients_18_years_old"/>
<artifact id="StructureDefinition/study-group" key="StructureDefinition-study-group" name="StudyGroup"/>
<artifact id="Group/32145" key="Group-32145" name="StudyGroup_Bariatric_Surgery_Trial_Enrollment_Group"/>
<artifact id="Group/46117" key="Group-46117" name="StudyGroup_DIBASY_Trial_Enrollment_Group"/>
<artifact id="StructureDefinition/summary-of-findings" key="StructureDefinition-summary-of-findings" name="SummaryOfFindings"/>
<artifact id="Composition/104215" key="Composition-104215" name="SummaryOfFindings: Bariatric Surgery Summary of Findings Example for GIN 2022"/>
<artifact id="StructureDefinition/summary-of-net-effect" key="StructureDefinition-summary-of-net-effect" name="SummaryOfNetEffect"/>
<artifact id="Composition/104383" key="Composition-104383" name="SummaryOfNetEffect: Bariatric Surgery Summary of Net Effect Contributions Example for GIN 2022"/>
<artifact id="StructureDefinition/systematic-review-eligibility-criteria" key="StructureDefinition-systematic-review-eligibility-criteria" name="SystematicReviewEligibilityCriteria"/>
<artifact id="Group/179619" key="Group-179619" name="SystematicReviewEligibilityCriteria_ADT_and_Docetaxel_vs_ADT_alone_for_metastatic_hormone_naive_prostate_cancer"/>
<artifact id="StructureDefinition/systematic-review-excluded-studies" key="StructureDefinition-systematic-review-excluded-studies" name="SystematicReviewExcludedStudies"/>
<artifact id="Library/179632" key="Library-179632" name="SystematicReviewExcludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer - Brian S. Alper"/>
<artifact id="StructureDefinition/systematic-review-included-studies" key="StructureDefinition-systematic-review-included-studies" name="SystematicReviewIncludedStudies"/>
<artifact id="Library/179618" key="Library-179618" name="SystematicReviewIncludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer"/>
<artifact id="EvidenceVariable/7751" key="EvidenceVariable-7751" name="Therapeutic-dose anticoagulation with heparin"/>
<artifact id="Group/33398" key="Group-33398" name="Type_2_diabetes_and_elevated_BMI_in_2016_meta_analysis"/>
<artifact id="StructureDefinition/variable-definition" key="StructureDefinition-variable-definition" name="VariableDefinition"/>
<artifact id="StructureDefinition/variable-definition-comparator-category" key="StructureDefinition-variable-definition-comparator-category" name="VariableDefinitionComparatorCategory"/>
<artifact id="StructureDefinition/variable-definition-role-subtype" key="StructureDefinition-variable-definition-role-subtype" name="VariableDefinitionRoleSubtype"/>
<artifact id="StructureDefinition/variable-definition-variable-role-code" key="StructureDefinition-variable-definition-variable-role-code" name="VariableDefinitionVariableRoleCode"/>
<artifact id="StructureDefinition/web-page-citation" key="StructureDefinition-web-page-citation" name="WebPageCitation"/>
<artifact id="Citation/179561" key="Citation-179561" name="WebPageCitation: A HEvKA Update Summary"/>
<page key="NA" name="(NA)"/>
<page key="many" name="(many)"/>
<page key="artifactassessment" name="ArtifactAssessment Profiles"/>
<page key="artifacts" name="Artifacts Summary"/>
<page key="citation" name="Citation Profiles"/>
<page key="composition" name="Composition Profiles"/>
<page key="downloads" name="Downloads"/>
<page key="evidence" name="Evidence Profiles"/>
<page key="evidencevariable" name="EvidenceVariable Profiles"/>
<page key="examples" name="Examples"/>
<page key="extensions" name="Extensions"/>
<page key="group" name="Group Profiles"/>
<page key="index" name="Introduction"/>
<page key="otherprofiles" name="Other Profiles"/>
<page key="profiles" name="Profiles"/>
<page key="toc" name="Table of Contents"/>
<page key="terminologies" name="Terminologies"/>
</specification>